Drugs / CAR-20/19-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04049383 | Oct 2020 → Jun 2025 | B-cell acute lymphoblastic leukemia, B-cell childhood acute lymphoblastic leukemia | Medical College of Wisconsin | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-20/19-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04049383 ↗ |
| Modality | Cell therapy | “CAR-T cell therapy directed against two B cell antigens (CD19 CD20)” NCT04049383 ↗ |
| Route | Intravenous | “administered either fresh or thawed after cryopreservation by IV injection” NCT04049383 ↗ |